Acute myeloid leukemia: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• FLT3 36
• TP53 9
• NPM1 27
• IDH 29
• KMT2A 20
• RUNX1 2
• CD123 19
• BCL-2 10
• ABL1 2
• CD33 17
• PI3K 3
• mTOR 0
• KIT 3
• JAK 1
• CD19 8
• MAPK 0
• STAT3 0
• ERK 0
• AKT 0
• CD38 6
• HDAC 2
• MYC 1
• NRF2 0
• PD-1 4
• PPAR 0
• CXCR4 0
• BRD4 0
• PD-L1 0
• RAS 0
• STING 1
• HIF-1 0
• TIM-3 0
• METTL3 0
• CD47 1
• CTNNB1 0
• JNK 0
• KRAS 0
• MEK 0
• PARP 3
• EZH2 0
• IL-6 2
• BRAF 0
• EGFR 0
• FTO 0
• HSP90 0
• PDGFR 0
• PTEN 0
• CDK4/6 0
• FGFR 2
• GPX4 0
• HMGB1 0
• NLRP3 0
• NRAS 0
• SHP2 0
• AMPK 0
• CD20 1
• IL-15 1
• MDM2 0
• PINK1 0
• PKM2 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 25+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Suspended

  Regorafenib in Combination With Venetoclax and Azacitidine for the Treatment of Patients With Relapsed or Refractory Acute Myeloid Leukemia

  NCT06454409· City of Hope Medical Center· Updated 20 Oct 2026

  “resources”Registry text, quoted unchanged. Source

• Terminated

  HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

  NCT03940352· Novartis Pharmaceuticals· Updated 10 Oct 2025

  “Business decision”Registry text, quoted unchanged. Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

• Terminated

  Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML)

  NCT05682170· K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.· Updated 19 Sept 2024

  “Sponsor decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study of BGB-11417 in Participants With Myeloid Malignancies

  NCT04771130· BeOne Medicines· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 39
• Mendelian Randomization Analysis 3
• CRISPR-Cas Systems 17
• Gene Expression Profiling 85
• Sequence Analysis, RNA 6
• Whole Genome Sequencing 7
• Exome Sequencing 1
• Proteomics 28
• Metabolomics 10
• Mass Spectrometry 3
• Flow Cytometry 87
• Immunohistochemistry 14
• Liquid Biopsy 1
• Circulating Tumor DNA 3
• Xenograft Model Antitumor Assays 159
• Positron-Emission Tomography 1
• Magnetic Resonance Imaging 11
• Machine Learning 33
• Deep Learning 12
• Cohort Studies 30
• Genome-Wide Association Study 3

• An integrated deep learning and molecular dynamics pipeline for the discovery of novel CDK8 inhibitors against acute myeloid leukaemia.

  SAR QSAR Environ Res, Aug 2026

• The role of computational pathology in predicting expression of selected immunohistochemical markers.

  Pol J Pathol, Jun 2026

• Detection of acute lymphocytic and myeloid leukaemia with optimized dimensionality reduction and deep learning classification framework.

  Curr Res Transl Med, Jun 2026

• Optimizing Deep Learning for Renal Mass Characterization in Challenging Cases: A Comparative Study of Spatial-Input Strategies and a Validated ROI-Only DLR Nomogram.

  Ann Surg Oncol, May 2026

• Adaptive multimodal learning for driver cognitive state monitoring using transformer-based fusion with personalized meta-learning and federated optimization.

  Sci Rep, May 2026

• Improving severity grading of chemotherapy-induced myelosuppression in AML via data-driven and model-based deep learning.

  NPJ Syst Biol Appl, Mar 2026

• A meta learning and task adaptive approach for drug target affinity prediction.

  Nat Commun, Mar 2026

• A deep learning ensemble framework for multi-subtype renal tumor classification using contrast-enhanced CT.

  Sci Rep, Jan 2026

• ProTCR: a protein language model-driven framework for decoding TCR-antigen recognition toward precision immunotherapies.

  Brief Bioinform, Jan 2026

• Deep learning in bone marrow cytomorphology: advances in segmentation, classification, and clinical translation.

  Med Oncol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.